RMD logo

RMD
Resmed Inc.

2,068
Mkt Cap
$27.64B
Volume
3.53M
52W High
$293.81
52W Low
$190.38
PE Ratio
18.37
RMD Fundamentals
Price
$190.57
Prev Close
$203.42
Open
$203.75
50D MA
$216.54
Beta
0.77
Avg. Volume
1.06M
EPS (Annual)
$9.51
P/B
4.26
Rev/Employee
$485,502.55
$37,643.00
Loading...
Loading...
News
all
press releases
ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
News Placeholder
More News
News Placeholder
Is the Options Market Predicting a Spike in ResMed Stock?
Investors need to pay close attention to RMD stock based on the movements in the options market lately.
Zacks
News Placeholder
Silver Economy Investing: Why the Healthcare Giants Are in Focus
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
Zacks
News Placeholder
Here's Why ResMed (RMD) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
News Placeholder
Birch Capital Management LLC Reduces Stock Holdings in ResMed Inc. $RMD
Birch Capital Management LLC reduced its stake in shares of ResMed Inc. (NYSE:RMD - Free Report) by 24.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 26,899 shares of the medical equipment provider's stock after selling 8,642 shares du...
MarketBeat
News Placeholder
PFA Pension Forsikringsaktieselskab Buys Shares of 188,393 ResMed Inc. $RMD
PFA Pension Forsikringsaktieselskab bought a new stake in ResMed Inc. (NYSE:RMD - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities...
MarketBeat
News Placeholder
ResMed Q3 Earnings Call Highlights
ResMed (NYSE:RMD) reported third-quarter fiscal 2026 results highlighted by revenue growth, gross margin expansion, and higher non-GAAP earnings per share, while also announcing a CFO transition and a planned tuck-in acquisition to expand beyond its core sleep apnea business. Leadership updates: CF...
MarketBeat
News Placeholder
Royal Bank Of Canada Forecasts Strong Price Appreciation for ResMed (NYSE:RMD) Stock
Royal Bank Of Canada lifted their price target on ResMed from $314.00 to $321.00 and gave the company an "outperform" rating in a research report on Friday...
MarketBeat
News Placeholder
ResMed (NYSE:RMD) Shares Down 6% on Analyst Downgrade
ResMed (NYSE:RMD) Shares Down 6% Following Analyst Downgrade...
MarketBeat
News Placeholder
Wells Fargo & Company Issues Pessimistic Forecast for ResMed (NYSE:RMD) Stock Price
Wells Fargo & Company lowered their price target on shares of ResMed from $270.00 to $227.00 and set an "equal weight" rating on the stock in a report on Friday...
MarketBeat
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available